Marta Rendon - Profile on Academia.edu (original) (raw)
Papers by Marta Rendon
Successful treatment of moderate to severe melasma with triple-combination cream and glycolic acid peels: a pilot study
Cutis, 2008
Triple-combination (TC) cream is a stable combination of fluocinolone acetonide 0.01%, hydroquino... more Triple-combination (TC) cream is a stable combination of fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05%, and currently is the only US Food and Drug Administration-approved drug for the topical treatment of melasma. Furthermore, it is the only US Food and Drug Administration-approved product containing hydroquinone. Anecdotal evidence suggests that improvements in melasma can be achieved with a multifactor approach involving TC cream with a variety of procedures. A pilot study was designed to evaluate the efficacy and safety of sequential treatment with TC cream and a series of glycolic acid (GA) peels in participants with moderate to severe melasma. Participants were treated with TC cream for 2 weeks before the alternating sequential treatment cycles with TC cream and GA peels began. A total of six 2-week cycles of TC cream and 5 GA peels were used. Efficacy and safety evaluations were conducted at weeks 6 and 12. Investigator global assessment (IGA) ratings indi...
Triple Combination Cream and Glycolic Acid Peels for the Treatment of Moderate to Severe Melasma
Journal of the Dermatology Nurses' Association, 2009
... Triple Combination Cream and Glycolic Acid Peels for the Treatment of Moderate to Severe Mela... more ... Triple Combination Cream and Glycolic Acid Peels for the Treatment of Moderate to Severe Melasma. Rendon, Marta MD1; Colon, Luz E. MS, CCRC, CCRA2; Johnson, Lori PhD2. ... Taylor, SC, Torok, H., Jones, T., Lowe, N., Rich, P., Tschen, E., et al. (2003). ...
Treatment of melasma
Journal of the American Academy of Dermatology, 2006
Treatment of melasma involves the use of a range of topical depigmenting agents and physical ther... more Treatment of melasma involves the use of a range of topical depigmenting agents and physical therapies. Varying degrees of success have been achieved with these therapies. The Pigmentary Disorders Academy (PDA) undertook to evaluate the clinical efficacy of the different treatments of melasma in order to generate a consensus statement on its management. Clinical papers published during the past 20 years were identified through MEDLINE searches and methodology and outcome assessed according to guidelines adapted from the US Preventive Services Task Force (USPSTF). The consensus of the group was that first-line therapy for melasma should consist of effective topical therapies, mainly fixed triple combinations. Where patients have either sensitivity to the ingredients or a triple combination therapy is unavailable, other compounds with dual ingredients (hydroquinone plus glycolic acid) or single agents (4% hydroquinone, 0.1% retinoic acid, or 20% azelaic acid) may be considered as an alternative. In patients who failed to respond to therapy, options for second-line therapy include peels either alone or in combination with topical therapy. Some patients will require therapy to maintain remission status and a combination of topical therapies should be considered. Lasers should rarely be used in the treatment of melasma and, if applied, skin type should be taken into account.
Journal of the American Academy of Dermatology, 2006
This article focuses on developments in pigmentary disorders that extend dermatologists' understa... more This article focuses on developments in pigmentary disorders that extend dermatologists' understanding of the field. Areas that are reviewed include the basic biochemistry, pharmacology, and physiology of the melanocortin system; melanosome development; genetic diseases associated with pigmentary disorders; pigmentary disorders secondary to systemic disease; drug-induced hyperpigmentation; environmental exposure to chemicals; and primary disorders of hyperpigmentation such as melasma and lentigines. Basic, clinical, and epidemiological research, along with a number of clinical case reports, were included in the review. This article also reports on the new health-related quality-of-life instrument (MELASQOL) that has been developed for women with melasma. ( J Am Acad Dermatol 2006;54:S255-61.)
Journal of the American Academy of Dermatology, 1992
the efficAcy And SAfety of SeR t AconAzole (Stz) nitRA te 2% cReAm in the tReA tment of tineA pediS in pA tientS with concomit Ant onychomycoSiS
The efficacy of sertaconazole in the treatment of tinea pedis in patients with co-morbid onychomy... more The efficacy of sertaconazole in the treatment of tinea pedis in patients with co-morbid onychomycosis was evaluated in a double-blind, vehicle-controlled six-week clinical trial in 23 patients, ages 43-83 years. Subjects applied either sertaconazole 2% or placebo cream twice daily to the affected areas for 4 weeks. Subjects were required to have clinic visits at baseline and weeks 2, 4 and 6. A mycobiological evaluation including KOH and DTM preparation, PAS of toenail(s) was performed at baseline. Fungal cultures were completed at visit 6. Only local side effects were recorded and reported by participants. Photographic evidence was also collected at baseline and throughout the study to document the progress of treatment. To date, 11 patients were randomized to receive sertaconazole and 12 to placebo. A total of 23 patients were enrolled. An assessment of the mycological cure rate and negative fungal cultures at week 6 was obtained in all subjects. Conclusion: Sertaconazole, an imi...
BACKGROUND The 7% lidocaine and 7% tetracaine (LT) peel is a self-occlusive, topical local anesth... more BACKGROUND The 7% lidocaine and 7% tetracaine (LT) peel is a self-occlusive, topical local anesthetic that has been proven safe and effective for use in conjunction with many dermatologic procedures, including cryotherapy, collagen injections, and various laser treatments. The product is applied directly to the skin as a cream that dries within 20 to 30 minutes of air exposure to form a flexible film membrane that is easily peeled off before surgery.
Successful treatment of moderate to severe melasma with triple-combination cream and glycolic acid peels: a pilot study
Cutis, 2008
Triple-combination (TC) cream is a stable combination of fluocinolone acetonide 0.01%, hydroquino... more Triple-combination (TC) cream is a stable combination of fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05%, and currently is the only US Food and Drug Administration-approved drug for the topical treatment of melasma. Furthermore, it is the only US Food and Drug Administration-approved product containing hydroquinone. Anecdotal evidence suggests that improvements in melasma can be achieved with a multifactor approach involving TC cream with a variety of procedures. A pilot study was designed to evaluate the efficacy and safety of sequential treatment with TC cream and a series of glycolic acid (GA) peels in participants with moderate to severe melasma. Participants were treated with TC cream for 2 weeks before the alternating sequential treatment cycles with TC cream and GA peels began. A total of six 2-week cycles of TC cream and 5 GA peels were used. Efficacy and safety evaluations were conducted at weeks 6 and 12. Investigator global assessment (IGA) ratings indi...
Triple Combination Cream and Glycolic Acid Peels for the Treatment of Moderate to Severe Melasma
Journal of the Dermatology Nurses' Association, 2009
... Triple Combination Cream and Glycolic Acid Peels for the Treatment of Moderate to Severe Mela... more ... Triple Combination Cream and Glycolic Acid Peels for the Treatment of Moderate to Severe Melasma. Rendon, Marta MD1; Colon, Luz E. MS, CCRC, CCRA2; Johnson, Lori PhD2. ... Taylor, SC, Torok, H., Jones, T., Lowe, N., Rich, P., Tschen, E., et al. (2003). ...
Treatment of melasma
Journal of the American Academy of Dermatology, 2006
Treatment of melasma involves the use of a range of topical depigmenting agents and physical ther... more Treatment of melasma involves the use of a range of topical depigmenting agents and physical therapies. Varying degrees of success have been achieved with these therapies. The Pigmentary Disorders Academy (PDA) undertook to evaluate the clinical efficacy of the different treatments of melasma in order to generate a consensus statement on its management. Clinical papers published during the past 20 years were identified through MEDLINE searches and methodology and outcome assessed according to guidelines adapted from the US Preventive Services Task Force (USPSTF). The consensus of the group was that first-line therapy for melasma should consist of effective topical therapies, mainly fixed triple combinations. Where patients have either sensitivity to the ingredients or a triple combination therapy is unavailable, other compounds with dual ingredients (hydroquinone plus glycolic acid) or single agents (4% hydroquinone, 0.1% retinoic acid, or 20% azelaic acid) may be considered as an alternative. In patients who failed to respond to therapy, options for second-line therapy include peels either alone or in combination with topical therapy. Some patients will require therapy to maintain remission status and a combination of topical therapies should be considered. Lasers should rarely be used in the treatment of melasma and, if applied, skin type should be taken into account.
Journal of the American Academy of Dermatology, 2006
This article focuses on developments in pigmentary disorders that extend dermatologists' understa... more This article focuses on developments in pigmentary disorders that extend dermatologists' understanding of the field. Areas that are reviewed include the basic biochemistry, pharmacology, and physiology of the melanocortin system; melanosome development; genetic diseases associated with pigmentary disorders; pigmentary disorders secondary to systemic disease; drug-induced hyperpigmentation; environmental exposure to chemicals; and primary disorders of hyperpigmentation such as melasma and lentigines. Basic, clinical, and epidemiological research, along with a number of clinical case reports, were included in the review. This article also reports on the new health-related quality-of-life instrument (MELASQOL) that has been developed for women with melasma. ( J Am Acad Dermatol 2006;54:S255-61.)
Journal of the American Academy of Dermatology, 1992
the efficAcy And SAfety of SeR t AconAzole (Stz) nitRA te 2% cReAm in the tReA tment of tineA pediS in pA tientS with concomit Ant onychomycoSiS
The efficacy of sertaconazole in the treatment of tinea pedis in patients with co-morbid onychomy... more The efficacy of sertaconazole in the treatment of tinea pedis in patients with co-morbid onychomycosis was evaluated in a double-blind, vehicle-controlled six-week clinical trial in 23 patients, ages 43-83 years. Subjects applied either sertaconazole 2% or placebo cream twice daily to the affected areas for 4 weeks. Subjects were required to have clinic visits at baseline and weeks 2, 4 and 6. A mycobiological evaluation including KOH and DTM preparation, PAS of toenail(s) was performed at baseline. Fungal cultures were completed at visit 6. Only local side effects were recorded and reported by participants. Photographic evidence was also collected at baseline and throughout the study to document the progress of treatment. To date, 11 patients were randomized to receive sertaconazole and 12 to placebo. A total of 23 patients were enrolled. An assessment of the mycological cure rate and negative fungal cultures at week 6 was obtained in all subjects. Conclusion: Sertaconazole, an imi...
BACKGROUND The 7% lidocaine and 7% tetracaine (LT) peel is a self-occlusive, topical local anesth... more BACKGROUND The 7% lidocaine and 7% tetracaine (LT) peel is a self-occlusive, topical local anesthetic that has been proven safe and effective for use in conjunction with many dermatologic procedures, including cryotherapy, collagen injections, and various laser treatments. The product is applied directly to the skin as a cream that dries within 20 to 30 minutes of air exposure to form a flexible film membrane that is easily peeled off before surgery.